logo

AASLD名家访谈丨Jasmohan Bajaj教授:慢加急性肝衰竭与晚期肝硬化中的免疫衰竭——从概念辨析到临床分层

国际肝病 发表时间:2026/11/20 15:32:47 浏览量:139

编者按

慢加急性肝衰竭(ACLF)与晚期肝硬化患者常呈现复杂的免疫紊乱状态,传统“全身炎症反应(SIRS)”与“免疫麻痹”框架已难以涵盖其全貌。近年来,免疫衰竭(immune failure)概念被提出,用以描述免疫系统的同时低反应与过度激活并存的矛盾状态。在 AASLD 2026 期间,《国际肝病》特邀美国弗吉尼亚联邦大学医学院Jasmohan Bajaj教授结合其大会发言,就免疫衰竭的定义边界、临床识别工具、菌群标志物的价值以及免疫调节策略的未来方向进行了深度对话。


01

《国际肝病》:ACLF与晚期肝硬化中“免疫衰竭”概念正被广泛讨论。它如何区别于传统的SIRS或免疫麻痹?在临床评估中,我们应如何准确识别这种“免疫失衡”状态?

Bajaj教授:感谢你们对这一议题的关注,这是一个极具临床相关性的重要话题。免疫衰竭本质上是免疫系统同时呈现低活性与高活性状态的综合体,因此免疫麻痹只是其中的一个组成部分。在肝硬化和 ACLF 患者中如何深度定义这一状态,则因两个关键因素而截然不同:第一,患者是否合并感染;第二,你愿意在多大深度上研究免疫衰竭。

我们可以通过开展全套检测——流式细胞术、循环及脾脏、骨髓等远隔部位的免疫细胞分析——可以绘制出极为深入的免疫图谱,但这在临床实践中几乎不可能实现。因此,中性粒细胞-淋巴细胞比值(NLR)作为一种粗略但实用的方法,可以在临床中用来界定当前免疫系统的受损程度。

需要注意的是,在合并感染的患者中情况又大不相同。某些感染——特别是真菌感染——意味着比尿路感染等更严重的免疫系统崩溃,技术层面上提示患者的免疫状态要糟糕得多。

Hepatology Digest: The concept of "immune failure" in ACLF and advanced cirrhosis is gaining increasing attention. How does it differ from traditional SIRS or immune paralysis? In clinical practice, how can we accurately identify this state of "immune imbalance"?

Professor Bajaj: Thank you for your interest in this topic; it is an issue of high clinical relevance. Immune failure is essentially a complex syndrome in which the immune system simultaneously exhibits both low and high activity; thus, immune paralysis represents only one component of this spectrum. How deeply we define this condition in patients with cirrhosis and ACLF depends critically on two factors: first, whether the patient has a concomitant infection; and second, the depth of investigation you are willing to pursue.

One could perform comprehensive testing — flow cytometry, analysis of immune cells from circulation and remote sites such as the spleen and bone marrow — to construct an extremely detailed immune map. However, this is hardly feasible in routine clinical practice. Therefore, the neutrophil-to-lymphocyte ratio (NLR), as a crude but practical measure, can be used clinically to gauge the current degree of immune impairment.

It should be noted that the situation is quite different in patients with coexisting infections. Certain infections — particularly fungal infections — signify a more profound immune system collapse than, for example, urinary tract infections, technically indicating a far worse immune status.


02

《国际肝病》:目前免疫衰竭的诊断仍缺乏统一标准。除了白细胞计数、细胞因子谱,肠道菌群标志物能否成为ACLF免疫衰竭早期预警与分层的实用工具?

Bajaj教授:肠道微生物组与免疫衰竭彼此紧密交织,而且不仅限于肠道。在肝硬化患者体内几乎所有部位——体循环、唾液、整个口腔乃至皮肤——都存在微生物定植。如果免疫系统功能正常,这些微生物本不应出现于上述部位。

正如我前面提到的,NLR 是评估免疫状态的实用方法,但除此之外,循环中的微生物标志物以及微生物组成分析也能帮助我们判断患者是否真正发生了免疫功能失调。这些微生物信号与传统的白细胞计数、细胞因子谱相结合,有望为 ACLF 免疫衰竭的早期预警与分层提供实用工具。

Hepatology Digest: Currently, there is no unified diagnostic criterion for immune failure. Beyond white blood cell counts and cytokine profiles, can gut microbial biomarkers serve as practical tools for early warning and stratification of immune failure in ACLF?

Professor Bajaj: The gut microbiome and immune failure are inextricably linked, and this extends beyond the gut. In patients with cirrhosis, microbial colonization can be found in virtually every site — the systemic circulation, saliva, the rest of the oral cavity, and even the skin. If the immune system were functioning normally, these microbes would not be present in such locations.

As I mentioned earlier, NLR is a practical method for assessing immune status. In addition, circulating microbial markers and microbial compositional analysis can help us determine whether a patient has truly developed immune dysfunction. The integration of these microbial signals with conventional white blood cell counts and cytokine profiles holds promise as a practical tool for early warning and stratification of immune failure in ACLF.


03

《国际肝病》:针对免疫衰竭,临床常面临感染控制与免疫过度抑制的矛盾(如激素、抗生素使用)。在ACLF治疗中,如何精准实施“免疫调节”而非单纯抗炎或免疫抑制?哪些策略最具前景?

Bajaj教授:这是一个非常重要但也极难回答的问题。如果怀疑患者存在感染,显然需要使用抗生素或抗真菌药物进行针对性治疗。然而,对于没有任何感染征象但白细胞计数升高或 NLR 增高的患者,目前没有任何策略允许我们盲目启动经验性抗生素,因为那只会加剧这类患者的抗生素耐药问题。

其他策略如修饰巨噬细胞、粪菌移植(FMT)已在探索中,但尚未达到临床常规应用阶段,尽管结果令人鼓舞。我们想要实现的是通过直接与间接两种方式调节免疫系统:直接调节即通过刚才提到的这些新兴手段;间接调节则是通过处理导致患者入院的基础病因——这本身也能改善免疫衰竭状态。

Hepatology Digest: In managing immune failure, clinicians often face the dilemma of balancing infection control with excessive immune suppression (e.g., use of corticosteroids or antibiotics). In ACLF treatment, how can we precisely implement "immunomodulation" rather than simply anti-inflammation or immunosuppression? Which strategies are most promising?

Professor Bajaj: This is a very important but extremely difficult question to answer. If an infection is suspected, targeted therapy with antibiotics or antifungal agents is clearly indicated. However, for patients without any signs of infection but with elevated white blood cell counts or increased NLR, no current strategy permits the blind initiation of empirical antibiotics, as this would only exacerbate antibiotic resistance in such patients.

Other strategies, such as macrophage modulation and fecal microbiota transplantation (FMT), are under investigation but have not yet reached routine clinical application, although results are encouraging. What we aim to achieve is immunomodulation through both direct and indirect approaches: direct modulation via the aforementioned emerging methods; indirect modulation by addressing the underlying etiology that led to the patient's hospitalization — which itself can improve the state of immune failure.


(来源:《国际肝病》编辑部)

声明:本文仅供医疗卫生专业人士了解最新医药资讯参考使用,不代表本平台观点。该信息不能以任何方式取代专业的医疗指导,也不应被视为诊疗建议,如果该信息被用于资讯以外的目的,本站及作者不承担相关责任。

版面编辑:张雪   责任编辑:付丽云
本内容仅供医学专业人士参考
相关搜索:  肝硬化

发表评论

提交评论
  • 相关推荐
  • 学术领域
返回
顶部